Whether you are a healthcare professional wanting to find out more about the latest FL trends, developments or trials or have recently attended one of our events (such as the FL Summit in Tel Aviv), please use this page as an expert resource to find the FL insight you need.
As we gather speed on our mission to find a cure for FL, the Knowledge Hub will grow, providing easy access to shared resources, news, developments and updates. Please check back regularly to join us on our journey.
If you have content that you would like to share on this site, let us know. Please send contributions to: info@theflf.org and ensure you have permission to share it if it is not your own work.
Educational workshop covering targeted therapies for FL With the ever-evolving landscape of targeted and cellular therapies, how can the most recent advances be incorporated into
The FLF’s Precision Medicine Programme research goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in
Enhancing Fas-mediated Bystander Killing of Follicular Lymphoma to prevent post-immunotherapy antigen escape. Follicular lymphoma (FL) is generally considered incurable, however, newer T-cell mediated therapies including
Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma Technical abstract: Follicular lymphoma (FL) is an indolent disease, and the primary clinical goal in
Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL. Technical abstract: CAR-T cell therapy resistance may appear linked to antigen
Engaging the inhibitory BTLA Receptor for the Treatment of Follicular Lymphoma Technical abstract: CAR T cell therapies have proven extremely powerful against B cell malignancies.
